Floxed Targeted Mouse Strain for Use in Conditional Deletion of the Irf8 Gene

IRF8, a member of interferon regulatory factor (IRF) family of transcription factors is a novel intrinsic transcriptional inhibitor of TH17-cell differentiation. TH17-cells are believed to be involved in the pathogenesis of various autoimmune/inflammatory diseases. These materials could be used to help define patterns of gene expression important for the development and function of cells including possible contributions to understanding: normal immune responses, inflammatory conditions, autoimmunity and anti-viral responses.

Potential Commercial Applications:		Competitive Advantages:
Target identification in B and T cell deficiency, macrophage defects and hematopoiesis A tool for investigating IRF8 mediated issues associated with inflammation and autoimmunity Investigative tool for development of potential therapeutics for lymphoma and Human Chronic Myeloid Leukemia		Mice with established germ line transmission for use in conditional deletion of the IRF8 gene in any cellt type

Inventors:

Herbert Morse (NIAID)  ➽ more inventions...


Intellectual Property:

Publications:
Ouyang, Xinshou, et al. https://www.nature.com/articles/ncomms1311

Collaboration Opportunity:
The Technology Transfer and Intellectual Property Office (TTIPO) is seeking parties interested in collaborative research to further co-develop this technology by identifying pharmacological compounds inhibiting CD62L shedding by using high throughput compound screening. For collaboration opportunities, please contact Chris Kornak at chris.kornak@nih.govor 1-240-627-3705.


Licensing Contact:
Christopher Kornak, J.D.
Email: chris.kornak@nih.gov
Phone: 240-627-3705

OTT Reference No: E-062-2012-0
Updated: Aug 27, 2019